Protease‐activated receptor antagonists prevent thrombosis when dual antiplatelet therapy is insufficient in an occlusive thrombosis microfluidic model-Reference-Cited by-同舟云学术

Protease‐activated receptor antagonists prevent thrombosis when dual antiplatelet therapy is insufficient in an occlusive thrombosis microfluidic model

Published:2022-03 Issue:3 Volume:6 Page:e12703
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Research and Practice in Thrombosis and Haemostasis

Author:

Berry Jess^ORCID,Harper Matthew T.^ORCID

Funder

National Centre for the Replacement Refinement and Reduction of Animals in Research

Publisher

Elsevier BV

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12703

Reference43 articles.

1. World Health Statistics 2021: Monitoring Health for the SDGs, Sustainable Development Goals,2021

2. Arterial thrombosis‐insidious, unpredictable and deadly;Jackson;Nat Med,2011

3. Current and future antiplatelet therapies: emphasis on preserving haemostasis;McFadyen;Nat Rev Cardiol,2018

4. State of the art of new P2Y12 antagonists;Cattaneo;Intern Emerg Med,2010

5. Platelet biology and functions: new concepts and clinical perspectives;van der Meijden;Nat Rev Cardiol,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PAR4 Antagonism in Patients With Coronary Artery Disease Receiving Antiplatelet Therapies;Arteriosclerosis, Thrombosis, and Vascular Biology;2024-04

2. Engineering Organ-on-a-Chip Systems for Vascular Diseases;Arteriosclerosis, Thrombosis, and Vascular Biology;2023-12

3. Illustrated Abstracts of the 5th EUPLAN International Conference;Research and Practice in Thrombosis and Haemostasis;2023-10